Dermatofibrosarcoma protuberans

Dermatofibrosarcoma protuberans (1986) Shneidman D +, Cancer 58, 1585 Edema (non-pitting)... [Pg.46]

Anti-CD34 (M) Dako 1 800 MWER Recognition of endothelial tumors, dermatofibrosarcoma protuberans, solitary fibrous tumors, and selected peripheral nerve sheath tumors and epithelioid sarcomas... [Pg.88]

Ma CK, Zarbo RJ, Gown AM. Immunohistochemical characterization of atypical fibroxanthoma and dermatofibrosarcoma protuberans. Am J Clin Pathol. 1992 97 478-483. [Pg.204]

FIGURE 13.26 Dermatofibrosarcoma protuberans (A) typically shows global reactivity for CD34 (B). [Pg.482]

Abenoza P, Lillemoe T. CD34 and factor Xllla in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. Am J Dermatopathol. 1993 15 429-434. [Pg.496]

Goldblum JR, Tuthill RJ. CD34 and factor Xllla—immunore-activity in dermatofibrosarcoma protuberans and dermatofibroma. Am J Dermatopathol. 1997 19 147-153. [Pg.496]

Wick MR, Ritter JH, Lind AC, et al. The pathological distinction between deep penetrating dermatofibroma and dermatofibrosarcoma protuberans. Semin Cutan Med Surg. 1999 18 91-98. [Pg.496]

Goldblum JR. Giant cell fibroblastoma a report of three cases with histologic and immunohistochemical evidence of a relationship to dermatofibrosarcoma protuberans. Arch Pathol Lab Med. 1996 120 1052-1055. [Pg.496]

Terrier-Lacombe MJ, Guillou L, Maire G, et al. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children a clinicopathologic comparative analysis of 28 cases with molecular data—a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2003 27 27-39. [Pg.496]

Mori T, Misago N, Yamamoto O, et al. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma. Dermatol. 2008 35 419-425. [Pg.496]

O Connell JX, Trotter MJ. Fibrosarcomatous dermatofibrosarcoma protuberans with myofibroblastic differentiation a histologically distinctive variant. Mod Pathol. 1996 9 273-278. [Pg.496]

Diaz-Cascajo C. Myoid differentiation in dermatofibrosarcoma protuberans and its fibrosarcomatous variant. J Cutan Pathol. 1997 24 197-198. [Pg.496]

Zamecnik M. Myoid cells in the fibrosarcomatous variant of dermatofibrosarcoma protuberans. Histopathology. 2000 36 186. [Pg.496]

Sigel JE, Bergfeld WF, Goldblum JR. A morphologic study of dermatofibrosarcoma protuberans expansion of a histologic profile. Cutan Pathol. 2000 27 159-163. [Pg.497]

Diedhiou A, Larsimont D, Vandeweyer E, et al. Fibrosarcomatous variant of dermatofibrosarcoma protuberans clinicopathologic analysis of 4 cases. Ann Pathol. 2001 21 164-167. [Pg.497]

Diwan AH, Skelton III HG, Horenstein MG, et al. Dermatofibrosarcoma protuberans and giant cell fibroblastoma exhibit CD99 positivity. J Cutan Pathol. 2008 35 647-650. [Pg.497]

Sachdev R, Sundram U. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans comparison with CD68, CD34, and factor Xllla. J Cutan Pathol. 2006 33 353-360. [Pg.497]

DLBCL, solitary fibrous tumor, synovial sarcoma, Kaposiform hemangiosarcoma, neurofibroma, schwannoma, nasopharyngeal carcinoma, dermatofibrosarcoma protuberans, spindle cell lipoma, rhabdomyosarcoma Follicular lymphoma (interfollicular area), Burkitt s lymphoma... [Pg.56]

Angiomyolipoma, cellular neurothekoma, dermatofibrosarcoma protuberans, renal oncocytoma and chromophobe carcinoma... [Pg.61]

Molecular Detection of Dermatofibrosarcoma Protuberans and Giant Cell Fibroblastoma... [Pg.146]

Dermatofibrosarcoma protuberans and its pediatric counterpart giant cell fibroblastoma are two tumors sharing many histological, immunohistochemical and cytogenetic features. [Pg.146]

Dermatofibrosarcoma protuberans is a slow infiltrative growing fibrohistiocytic tumor mainly affecting adults between the 3" and 4 decade and appears in the deep dermis, composed of proliferating uniform small spindled cells arranged in a repetitive storiform pattern. [Pg.146]

Dermatofibrosarcoma protuberans and giant cell fibroblastoma share the same immunohistochemical profile and show positive reaction with the specific antibodies to CD34, PDGF and vimentin. Both tumors reveal low or intermediate malignant behavior and tens to local recurrence after incomplete excision and characterized by very low metastatic tendency, which generally occurs after an inadequate surgical treatment. [Pg.146]

Dermatofibrosarcoma protuberans and giant cell fibroblastoma are associated with the novel and specific unbalanced t(17 22)(q22 ql3) translocation generating the COLIAI-PDGFB fusion transcript, occasionally with a supernumerary ring chromosome r (17 22) as a result of this translocation. [Pg.146]

As the t(17 22)(q22 ql3) translocation is specific for both tumors and has not been described in association with any other benign or malignant lesions, the amplification of the COLlAl-PDGFB-fusion transcript can be used as a molecular marker to distinguish dermatofibrosarcoma protuberans and giant cell fibroblastoma from other tumors with similar morphology. [Pg.146]

Navarro, M Simon, M.-P., Migeon, C. et al. (1998) COLIAI-PDGFB fusion in a ring chromosome 4 found in a dermatofibrosarcoma protuberans. Genes Chromosomes Cancer, 23, 263-266. [Pg.259]

Z. (2007) Transformed dermatofibrosarcoma protuberans real time polymerase chain reaction detection of COLIAI-PDGFB fusion transcripts in sarcomatous areas. J Clin Pathol, 60, 190-194. [Pg.259]

Takahira, T., Oda, Y., Tamiya, S. et a . (2007) Detection of COLIAI-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans. Mod Pathol, 20, 668-675. [Pg.260]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...